Recent 8-K filings for SIGA

• May 7, 2026, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01 ◈ Earnings Releases

  SIGA Q1 net loss widens to $3.5M; revenue falls to $6.2M

  Product sales $3.5M vs $5.8M YoY; total revenue $6.2M vs $7.0M.

• March 26, 2026, 7:59 PM ET dividend materiality 0.65 positive item 8.01

  SIGA declares special $0.60/share dividend payable April 23

  Special one-time cash dividend of $0.60 per common share declared.

• March 10, 2026, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  SIGA 2025 product revenue $88M, down 34% YoY; net income $23.3M vs $59.2M

  Product revenues of $88M in 2025, down from $133M in 2024; total revenues $94.6M.

• November 6, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  SIGA reports Q3 2025 net loss of $6.4M on $2.6M revenue, down from $1.3M income YoY

  Q3 2025 product sales fell to $0.9M from $8.9M YoY; total revenue $2.6M vs $10.0M.

• August 5, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  SIGA reports Q2 2025 product revenues $79.1M, net income $35.5M, EPS $0.49; new BARDA funding $27M

  Record quarterly total revenue of $195.5M, up 29.4% from $151.1M in Q2 2024, including $79.1M product sales

• May 8, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  SIGA Q1 2025 net loss $0.4M, revenue $7.0M; special dividend $0.60

  Q1 2025 total revenues $7.0M (down 72% YoY); net loss $0.4M ($0.01 EPS) vs net income $10.3M ($0.14 EPS) in Q1 2024.

• April 8, 2025, 7:59 PM ET dividend materiality 0.60 positive item 8.01

  SIGA declares special one-time dividend of $0.60/share payable May 15, 2025

  Special one-time cash dividend of $0.60 per share declared on April 8, 2025.

• March 11, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  SIGA FY2024 net income $59.2M ($0.82 EPS); product sales $133M, up 2% YoY

  Product sales were $133M in 2024 vs $130.7M in 2023, including $100M to US SNS.

• December 10, 2024, 6:59 PM ET other material materiality 0.85 negative item 8.01item 9.01

  SIGA's tecovirimat fails mpox lesion resolution endpoint; STOMP enrollment stopped

  Tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox; DSMB recommended stop enrollment.

• November 7, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  SIGA reports Q3 product revenues $8.9M; receives $122M in procurement orders from US government

  Product revenues $8.9M (Q3 2024) vs $8.0M YoY; total revenues $10.0M.

• September 20, 2024, 7:59 PM ET leadership materiality 0.60 negative item 5.02 ◈ executive_change ×2

  SIGA Technologies CMO and Board Member Jay Varma begins indefinite leave

  Dr. Jay K. Varma commenced indefinite leave as EVP, Chief Medical Officer and board member on Sept 19, 2024.

• August 15, 2024, 7:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  SIGA's tecovirimat misses primary endpoint in PALM 007 mpox trial; shows benefit in subgroups

  PALM 007 did not meet primary endpoint of statistically significant improvement in time to lesion resolution.

• August 1, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  SIGA Q2 product sales $20.7M, net income $1.8M; receives $113M U.S. order in July

  Product sales $20.7M in Q2 (vs $1.3M prior year); total revenues $21.8M; net income $1.8M or $0.03 diluted EPS.

• July 19, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  SIGA receives $113M US government procurement order for oral TPOXX

  U.S. HHS exercised procurement option for ~$113M of oral TPOXX treatment courses under current contract.

• May 7, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  SIGA Q1 2024: product sales $23.9M, net income $10.3M, $0.60 special dividend

  Product sales $23.9M vs $5.7M YoY; total revenues $25.4M vs $8.3M.

• March 12, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  SIGA Technologies reports 2023 product sales of $131M, pre-tax operating income $84M; declares $0.60 special dividend

  Product sales increased 51% YoY to $130.7M (including supportive services) for the year ended Dec 31, 2023.

• January 22, 2024, 6:59 PM ET leadership materiality 0.70 positive item 5.02item 7.01item 9.01 ◈ executive_change

  SIGA appoints Diem Nguyen as CEO effective Jan 27, 2024; Phil Gomez retires

  Diem Nguyen appointed CEO and board member effective Jan 27, 2024; Phil Gomez retires Jan 26.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

9 positive 8 negative 7 neutral

source · SIGA on sec.gov